Two anxieties share one question. Someone losing faster than the people around them asks whether it is dangerous; someone losing slower asks whether the medicine is failing them. Both are asking about pace, and pace is where comparison does the most damage, because the number means something different in every body. The honest starting point is a checkable fact: no label in this class defines a correct speed.
What the labels say about speed, which is nothing
The current US labels for Wegovy, Ozempic, the shared Rybelsus and Ozempic tablets label, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, Byetta and Foundayo, as they stood on November 4, 2026, state no target rate of weight loss, no maximum rate, and no rate at which loss becomes a concern. There is no pounds-per-week figure anywhere in the labelling for this class. That is worth saying plainly, because it is the answer to the question as most people ask it: the document that governs these medicines draws no line on speed.
The widely repeated figure of one or two pounds a week is general weight-management guidance that circulates far beyond this class of medicines. It does not appear in any GLP-1 label, and treating it as a rule these medicines are supposed to obey gives it an authority it does not have. A guideline from outside the labelling can still be a reasonable thing to discuss with a clinician; it is simply not a fact about these drugs.
The one place rapid loss appears, read closely
The only engagement with rapid loss in any of these labels is the gallbladder, and the sentence rewards a second read. The Wegovy and Saxenda labels both state that “substantial or rapid weight loss can increase the risk of cholelithiasis”, and then add that the incidence of acute gallbladder disease was greater in treated patients than in placebo patients, “even after accounting for the degree of weight loss.”
Two claims sit inside that sentence, and they point in different directions. The first is the general clinical point people have heard: losing weight quickly raises gallstone risk, on a GLP-1 or off one. The second is the part that gets skipped. If the gallbladder excess persisted after accounting for how much weight was lost, then the rate of loss alone does not explain it, and something else about being on the medicine is involved in whatever the labels are describing. The Zepbound and Foundayo labels carry an acute gallbladder disease warning without the rapid-loss clause at all. The gallbladder subject is covered properly, including what warrants urgent care, at Gallbladder Symptoms on a GLP-1: What to Watch For, and the detail belongs there rather than here.
The other consequences people attach to a fast pace each have their own page on this site, and each is worth reading in full there. Bone and fracture data during weight loss is covered at Rapid Weight Loss and Your Bones. Protecting lean mass, with the protein and strength training that go with it, is the subject of Two Days of Strength Training: The GLP-1 Muscle Insurance. Hair shedding during periods of rapid loss is laid out at Hair Shedding During Rapid Weight Loss: What the Data Says. And eating too little, which a suppressed appetite makes easy and which undermines everything else, is covered at Eating Too Little on a GLP-1: Why It Happens and What to Watch. None of these pages defines a speed either; they describe what the evidence shows about the consequences, which is a different and more answerable question.
Reading your own rate without turning it into a target
A rate is a slope, and a slope needs more than two points. Two weigh-ins produce a difference, and the difference is dominated by water, sodium, a big meal, an empty gut and the ordinary noise of a scale; the method is laid out at How to Read a Weight Trend Line. Over about four weeks, the readings average out into something with a direction, and that direction is the only pace worth discussing with anyone, including yourself.
Whether to weigh daily or weekly is a preference, not a correctness question, and the trade-offs are compared at Daily or Weekly Weigh-Ins on a GLP-1? Both Work, Differently. What matters for rate is that whichever readings you take end up in one place, on one chart, long enough for a slope to exist. The failure mode is not weighing wrong; it is computing a speed from a number that moved for reasons unrelated to fat loss and then reacting to it.
Why your pace and everyone else's are not comparable
The trials behind these medicines produced averages, and the averages hide a spread that surprises people who only see the headlines. Dose moves the number, and many people are on a starting dose or partway up a ladder that takes months. Starting point moves it, because the same weekly loss is a different percentage of a different body, and the physiology of loss interacts with that percentage. Time on the medicine moves it, which is why loss typically slows as months pass, a pattern explained properly at Why Weight Loss Always Slows Down and set in the month-by-month arc at Month by Month: What GLP-1 Results Actually Look Like.
Then there is everything the trials could not control, which is most of life. Against that backdrop, comparing your week to a stranger's week on social media is close to meaningless, a habit examined at Comparing Your Progress to Other People Online. The clinical end of the same problem, what the trials call weak response and what it does and does not mean, is covered at Not Responding to Your GLP-1? What the Trials Call It. Both directions of worry deserve even treatment: faster is not self-evidently better, and slower is not failure. Neither is a reason to change anything without a prescriber.
What belongs in a prescriber conversation
Two things earn a place at the next appointment. The first is a rate that changed sharply, in either direction, because a slope that bends is more informative than a slope that is merely steep. The second is loss alongside feeling unwell, because the number and the feeling are both data and neither cancels the other; that disagreement has its own page at When the Data and How You Feel Disagree. A dated log makes both easy to raise: a prescriber shown four months of entries can see the bend for themselves, which is a better conversation than an adjective. What a prescriber does with any of it, including whether a rate warrants a change in treatment, is their judgement, made with a full history that no article and no chart substitutes for.
Frequently asked questions
Is there a maximum safe rate of weight loss on a GLP-1?
No label in the class states one. As of November 4, 2026, the current US labels for Wegovy, Ozempic, the shared Rybelsus and Ozempic tablets label, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, Byetta and Foundayo contain no pounds-per-week figure, no target rate, no maximum rate, and no rate at which loss becomes a concern. The widely repeated one or two pounds a week figure is general weight-management guidance, not something these medicines are held to.
Does losing weight quickly on a GLP-1 cause gallstones?
The Wegovy and Saxenda labels state that substantial or rapid weight loss can increase the risk of cholelithiasis, which is the general clinical point people have heard. The same sentence also reports that acute gallbladder disease was more common in treated patients than in placebo patients even after accounting for the degree of weight loss, so rate alone does not explain the difference. The gallbladder subject in full, including when to seek care, is covered in the gallbladder awareness guide.
How should I work out my own rate of weight loss?
As a slope over weeks, not a difference between two weigh-ins. Daily weight moves for reasons that have nothing to do with loss, so a rate built from two numbers is mostly noise. A trend line over about four weeks gives a slope you can actually read, and whether you weigh daily or weekly matters less than feeding whichever readings you have into one consistent trend. The method is laid out in the weight trend lines guide.
Is my GLP-1 not working if my weight loss is slower than other people's?
Pace varies enormously between people on the same medicine at the same dose, because dose, starting point and time on the medicine all move the number, along with everything the trials could not control. Slower is not failure and faster is not self-evidently better. A change in medication belongs with a prescriber, never with a comparison to someone else's chart, and the clinical side of weak response is covered in the non-responder guide.
When should I mention my rate of weight loss to my prescriber?
Two situations are worth raising: a rate that changed sharply, in either direction, and loss alongside feeling unwell. Both are exactly the kind of thing a prescriber can work with, because they combine a number with how you are doing, and a dated log makes the conversation concrete. When the number and the feeling disagree, that disagreement itself is worth describing rather than smoothing over.